Intravenous immunoglobulin in septic shock: Review of the mechanisms of action and meta-analysis of the clinical effectiveness

Minerva Anestesiologica

Volumn 82, Issue 5, 2016, Pages 559-572

  Busani, Stefano ^a   Damiani, Elisa ^b   Cavazzuti, Ilaria ^a   Donati, Abele ^b   Girardis, Massimo ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Immunoglobulins; Immunomodulation; Intravenous; Sepsis; Septic; Shock

Indexed keywords

ALBUMIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; IMMUNOGLOBULIN A;

ANTIINFLAMMATORY ACTIVITY; CLINICAL EFFECTIVENESS; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; META ANALYSIS; MORTALITY; MORTALITY RISK; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; IMMUNOLOGY; TREATMENT OUTCOME;

HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84983196444     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
2. Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 2009;13:R103.
3. Hotchkiss RS, Sherwood ER. Immunology. Getting sepsis therapy right. Science 2015;347:1201-2.
4. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013;13:260-8.
5. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008;34:17-60.
6. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
7. Soares MO, Welton NJ, Harrison DA, Peura P, Shankar-Ari M, Harvey SE et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess 2012;16:1-186.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
9. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
10. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al. The SO FA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
11. Elebute EA, Stoner HB. The grading of sepsis. Br J Surg 1983;70:29-31.
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
13. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Chichester, UK: John Wiley and Sons, Ltd:; 2009.
14. Lipsey MW, Wilson DB, editors. Practical Meta-Analysis. Vol 49. Thousand Oaks, CA, USA : Sage; 2001.
15. Higgins JP, Thompson SJ, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
16. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001;54:1046-55.
17. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review:Immunoglobulin therapy for sepsis-biological plausibility from a critical care perspective. Crit Care 2012;16:206.
18. Berlot G, Rossini P, Turchet F. Biology of immunoglobulins. Transl Med UniSa 2015;11:24-7.
19. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89.
20. Nimmerjahn F, Ravetch JV. FcgammaRs in health and disease. Curr Top Microbiol Immunol 2011;350:105-25.
21. Nagelkerke SQ, Kuijpers TW. Immunomodulation by IVIg and the Role of Fc-Gamma Receptors:Classic Mechanisms of Action after all? Front Immunol 2014;5:674.
22. Pincetic A, Bournazos S, Dilillo DJ, Maamary J, Wang TT, Dahan R, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 2014;15:707-16.
23. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. The long elusive IgM Fc receptor, FcmuR. J Clin Immunol 2014;34(Suppl 1):S35-45.
24. Ehrenstein MR, Notley CA. The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol 2010;10:778-86.
25. Ferry H, Potter PK, Crockford TL, Nijnik A, Ehrenstein MR, Walport MJ et al. Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J Immunol 2007;178:2916-22.
26. Nguyen TT, Elsner RA, Baumgarth N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J Immunol 2015;194:1489-502.
27. Stehr SN, Knels L, Weissflog C, Schober J, Haufe D, Lupp A et al. Effects of IGIGM-enriched solution on polymorphonuclear neutrophil function, bacterial clearance, and lung histology in endotoxemia. Shock 2008;29:167-72.
28. Nakamura K, Doi K, Okamoto K, Arai S, Ueha S, Matsushima K et al. Specific antibody in IV immunoglobulin for postsplenectomy sepsis. Crit Care Med 2013;41:e163-70.
29. Barratt-Due A, Sokolov A, Gustavsen A, Hellerud BC, Egge K, Pischke SE et al. Polyvalent immunoglobulin significantly attenuated the formation of IL-1beta in Escherichia coli-induced sepsis in pigs. Immunobiology 2013;218:683-9.
30. Ates I, Dogan N, Aksoy M, Halici Z, Gundogdu C, Keles MS. The protective effects of IgM-enriched immunoglobulin and erythropoietin on the lung and small intestine tissues of rats with induced sepsis: biochemical and histopathological evaluation. Pharm Biol 2015;53:78-84.
31. Esen F, Senturk E, Ozcan P, Ahishali B, Arican N, Oran N et al. Intravenous immunoglobulins prevent the breakdown of the blood-brain barrier in experimentally induced sepsis. Crit Care Med 2012;40:1214-20.
32. Ishikura H, Nakamura Y, Kawano Y, Tanaka J, Mizunuma N, Ohta D et al. Intravenous immunoglobulin improves sepsis-induced coagulopathy: a retrospective, single-center observational study. J Crit Care 2015;30:579-83.
33. Rossmann FS, Kropec A, Laverde D, Saaverda FR, Wobser D, Hoebner J. In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens. Infection 2015;43:169-75.
34. Toth I, Mikor A, Leiner T, Molnar Z, Bogar L, Szakmany T. Effects of IgM-enriched immunoglobulin therapy in septic shock-induced multiple organ failure: pilot study. J Anesth 2013;27:618-22.
35. Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: pilot study and interim analysis of a randomized trial. Anti Infect Drugs Chemother 1995;13:129-34.
36. Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol 1991;11:363-8.
37. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
38. De Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: A therapeutic trial in septic intensive care unit patients. Crit Care Med 1988;16:23-6.
39. Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R, Abakumov MM. High-dose intravenous IgG for treatment of severe surgical infections. Dig Surg 1996;13:430-4.
40. Grundmann R, Hornung M. Immunoglobulin therapy in patients with endotoxemia and postoperative sepsis-a prospective randomized study. Prog Clin Biol Res 1988;272:339-49.
41. Hentrich M, Fehnle K, Ostermann H, Kienast J, Cornely O, Salat C, et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med 2006;34:1319-25.
42. Karatzas S, Boutzouka E, Venetsanou K, Myrianthefs P, Fildisis G, Baltopoulos G. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view. Crit Care 2002;6:543-4.
43. Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections: A randomized study in patients with septicaemia and pneumonia. Vox Sang 1981;40:329-37.
44. Masaoka T, Hasegawa H, Takaku F. The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections. Jpn J Chemother 2000;48:199-217.
45. Rodriguez A, Rello J, Neira J, Maskin B, Ceraso D, Vasta L, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 2005;23:298-304.
46. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauthmann D, Balikcioglu S, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 1991;19:1104-13.
47. Spannbrucker N, Munch HG, Kunze R, Vogel F. Auswirkungen von immunglobulinsubstitution bei sepsis. Intensivmedizin 1987;6:314.
48. Tugrul S, Ozcan PE, Akinci O, Seyhun Y, Cagatay A, Cakar N, et al. The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis. Crit Care 2002;6:357-62.
49. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701.
50. Wesoly C, Kipping N, Grundmann R: Immunglobulintherapie der postoperativen sepsis. Z Exp Chir Transplant Kunstliche Organe 1990;23:213-6
51. Yakut M, Cetiner S, Akin A, Tan A, Kaymakcioglu N, Simsek A, et al. Sepsisdeki hastalarda immunglobulin G (IgG) kullaniminin mortalite oranina etkisi. GATA GATAGATA Bulteni 1998;40:76-81.
52. Shankar-Hari M, Culshaw N, Post B, Tamayo E, Andaluz-Ojeda D, Bermejo-Martín JF, et al. Intensive Care Med. Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. Intensive Care Med 2015;41:1393-401.
53. Bermejo-Martín JF, Rodriguez-Fernandez A, Herrán-Monge R, Andaluz-Ojeda D, Muriel-Bombín A, Merino P, et al. GRECIA Group (Grupo de Estudios y Análisis en Cuidados Intensivos). Immunoglobulins IgG1, IgM and IgA: A synergistic team influencing survival in sepsis. J Intern Med 2014;276:404-12.
54. Justel M, Socias L, Almansa R, Ramírez P, Gallegos MC, Fernandez V, et al. IgM levels in plasma predict outcome in severe pandemic influenza. J Clin Virol 2013;58:564-7.
55. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85.
56. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. AL BIOS Study Investigators:Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014;370:1412-21.
57. Alejandria MM, Lansang MAD, Dans LF, Mantaring JB III : Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013;9:CD001090.
58. Damiani E, Donati A, Serafini G, RinalDi L, Adrario E, Pelaia P, et al. Effect of performance improvement programs on compliance with sepsis bundles and mortality: a systematic review and meta-analysis of observational studies. PLoS One 2015;10:e0125827.
59. Almansa R, Tamayo E, Andaluz-Ojeda D, Nogales L, Blanco J, Eiros JM, et al. The original sins of clinical trials with intravenous immunoglobulins in sepsis. Crit Care 2015;19:90.
60. Taccone FS, Stordeur P, De Backer D, Creteur J, Vincent JL. Gamma-globulin levels in patients with community-acquired septic shock. Shock 2009;32:379-85.
61. Ahsan N. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy. J Nephrol 1998;11:157-61.
62. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004;38:2059-67.